PRESS RELEASE: First Patients Tested with InVisionFirst®-Lung in EORTC Sponsored Phase II NSCLC Study
Inivata’s InVisionFirst®-Lung is being used for ctDNA testing and monitoring [...]
Webinar: How can current EU policy initiatives pave the way towards treatment optimisation as part of health systems?
The EORTC and the BioMed Alliance, together with MEP Maria [...]
EORTC lobbies for reducing the economic burden of cancer by optimising treatment for cancer patients
by Davi Kaur, EORTC Head of Communications Over the last [...]
Pivoting from physical to virtual meetings, engaging with a global audience
The EORTC events team have had a challenging year, this [...]
The 1553-SPECTA translational research platform registered the 1000th patient
The 1553-SPECTA translational research platform registered the 1000th patient on [...]
Genito-urinary cancer research looks to the future
The EORTC webinar on the future of genito-urinary cancer research [...]
European Cancer Summit supports a reorientation of research approaches to address the needs of patients and health systems
Br Mary Rice, EORTC Communication Consultant The European Cancer Summit, [...]
15 year follow up of EORTC 22922/10925 phase III trial shows reduction in breast cancer mortality and recurrence but does not confirm improved overall survival Gallery15 year follow up of EORTC 22922/10925 phase III trial shows reduction in breast cancer mortality and recurrence but does not confirm improved overall survival
15 year follow up of EORTC 22922/10925 phase III trial shows reduction in breast cancer mortality and recurrence but does not confirm improved overall survival
by Davi Kaur, EORTC Head of Communications Results of the [...]
A new approach to the use of datasets is needed to bring the best evidence to patients and society
By Mary Rice, EORTC Communication Consultant The debate around the [...]
CAREFOR: safeguarding the future of independent academic research in Europe for the benefit of cancer patients
CAREFOR: the Clinical Academic Cancer Research Forum, was created, in [...]
